新推荐的多囊卵巢窦卵泡计数截断值对成人多囊卵巢综合征诊断的影响
该病例对照研究基于Rotterdam标准,评估新推荐窦卵泡计数(AFC)≥20截断值对多囊卵巢综合征(PCOS)诊断的影响。在需存在多囊卵巢(PCO)才能诊断的表型中,约48.2%被新截断值排除,但这些女性代谢和激素状况比对照更差,且与未排除患者难以区分。
要点
- 新AFC截断值使约半数需PCO表型的PCOS患者被排除诊断。
- 被排除女性代谢和雄激素状况仍比对照差。
- 被排除女性与高AFC组在主要代谢激素参数上无差异。
核心结论
- 采用新推荐AFC截断值后,相当比例因月经不规律或高雄激素症状就诊的PCOS女性可能被归类为无PCOS。
研究设计与样本
- 病例对照研究,纳入1390例20-40岁成人PCOS患者和562例无PCOS的绝经前对照。
- 超声使用宽频5-9 MHz经阴道探头,中心频率8 MHz。
主要发现
- 在月经不规律+PCO或HA+PCO表型患者中,约48.2%(255/529)被新截断值排除PCOS,相当于全部成人患者的18.3%(255/1390)。
- 被排除女性(低AFC组,n=255)代谢状况比对照更差且雄激素化更明显。
- 低AFC组与高AFC组(n=101)在BMI、糖尿病分类状态及胰岛素抵抗、代谢综合征和高雄激素血症患病率等主要参数上无法区分。
关键数值与推荐
- Rotterdam标准中PCO定义为卵巢体积>10 cm3或直径2-9 mm卵泡≥12个。
- 新国际PCOS指南推荐成人使用高频探头(含8 MHz)时AFC≥20作为PCO阈值。
- 卵巢体积≥10 cm3时无论AFC均可诊断PCO,仅分析卵巢体积<10 cm3者。
临床怎么用
- 对新截断值下被排除的患者,应控制月经或高雄激素症状并定期评估新发或加重的PCOS相关症状或代谢异常。
局限性
- 不能排除AFC评估中观察者间和观察者内变异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: What is the impact of the newly recommended antral follicle count (AFC) cutoff for polycystic ovary (PCO) on the diagnostic status of polycystic ovary syndrome (PCOS)? SUMMARY ANSWER: Among patients with phenotypes requiring the presence of PCO for diagnosis, approximately half (48.2%) were excluded from having PCOS based on the new AFC cutoff, although these excluded women had worse metabolic and hormonal profiles than the controls and were indistinguishable from the remaining patients with regard to major hormonal and metabolic parameters. WHAT IS KNOWN ALREADY: In the Rotterdam criteria, PCO is defined as either 12 or more follicles measuring 2-9 mm in diameter or an increased ovarian volume >10 cm3. Recently, an international PCOS guideline development group recommended an AFC threshold for PCO of ≥20 in adult women when using transducers with a high-resolution frequency, including 8 MHz. STUDY DESIGN, SIZE, DURATION: The current study used a case control design. PARTICIPANTS/MATERIALS, SETTING, METHODS: PCOS was diagnosed according to the Rotterdam criteria. Ultrasonography examinations were conducted with wide band frequency (5-9 MHz) transvaginal transducers and the centre frequency was 8 MHz. In patients who show both irregular menstruation and hyperandrogenism (HA), a diagnosis of PCOS can be made irrespective of the ovarian criteria change. Patients who were diagnosed according to HA and PCO (n = 86) or irregular menstruation and PCO (n = 443) were initially included among a total of 1390 adult women with PCOS (aged 20-40 years). Regardless of the AFC, if the ovarian volume is ≥10 cm3, a diagnosis of PCO can still be made. Thus, only patients who had an ovarian volume of <10 cm3 were analysed. Subjects who had an AFC of 12-19 and an ovarian volume <10 cm3 were designated as the 'low AFC group' (n = 255) and were the main focus of the study because they were excluded from having PCOS based on the new cutoff. Subjects with an AFC ≥20 and an ovarian volume <10 cm3 were designated as the 'high AFC group' (n = 101). A total of 562 premenopausal women without PCOS were enrolled as controls. MAIN RESULTS AND THE ROLE OF CHANCE: Among patients with irregular menstruation and PCO or HA and PCO phenotypes, approximately half (48.2%, 255/529) were excluded from having PCOS, which corresponded to one-fifth (18.3%, 255/1390) of the total adult patients. However, compared to the control group, these excluded women had worse metabolic profiles and were more androgenised. Notably, they were indistinguishable from the 'high AFC group' with regard to major hormonal and metabolic parameters (BMI and diabetic classification status, and the prevalence of insulin resistance, metabolic syndrome and HA). LIMITATIONS, REASONS FOR CAUTION: We cannot exclude the possibility of inter- and intraobserver variation in the evaluation of AFC. WIDER IMPLICATIONS OF THE FINDINGS: With the newly recommended follicle count cutoff, a substantial proportion of women with PCOS might be classified as not having PCOS despite visiting a hospital due to irregular menstruation or hyperandrogenic symptoms. A practical approach to them would involve controlling the menstrual or hyperandrogenic symptoms in hand and regularly evaluating them regarding newly developed or worsening PCOS-related symptoms or metabolic abnormalities. STUDY FUNDING/COMPETING INTEREST(S): This study was supported by a grant from the Seoul National University Hospital Research Fund (No. 2520140090), Republic of Korea. The authors have no conflicts of interest to disclose. TRIAL REGISTRATION NUMBER: Not applicable.
引用
- Kim JJ, Hwang KR, Chae SJ, et al. Impact of the newly recommended antral follicle count cutoff for polycystic ovary in adult women with polycystic ovary syndrome. Hum Reprod. 2020. PMID: 32211797. doi:10.1093/humrep/deaa012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。